Efficacy and Safety in Reducing the Dosage of Insulin Secretagogues with Addition of Pioglitazone in Patients with Type 2 Diabetes

DOI Web Site 23 References
  • Mori Hiroko
    The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health
  • Okada Yosuke
    The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health
  • Yoshimura Akiko
    The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health
  • Arao Tadashi
    The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health
  • Nishida Keiko
    The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health
  • Tanaka Yoshiya
    The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health

Bibliographic Information

Other Title
  • 2型糖尿病患者におけるピオグリタゾン追加投与によるインスリン分泌促進薬減量の有効性と安全性
  • 診断・治療(食事・運動・薬物治療) 2型糖尿病患者におけるピオグリタゾン追加投与によるインスリン分泌促進薬減量の有効性と安全性
  • シンダン ・ チリョウ(ショクジ ・ ウンドウ ・ ヤクブツ チリョウ) 2ガタ トウニョウビョウ カンジャ ニ オケル ピオグリタゾン ツイカ トウヨ ニ ヨル インスリン ブンピ ソクシンヤク ゲンリョウ ノ ユウコウセイ ト アンゼンセイ

Search this article

Abstract

We analyzed the effects of pioglitazone coadministered reducing stimulators of insulin secretion on glucose and lipid metabolism, hypoglycemia episode frequency, and body weight in 109 outpatients with type 2 diabetes. A decrease in HbA1c of 0.5% or more was considered an effective response and HbA1c deterioration of 0.5% or more represented an invalid response, and the remaining were an invariable response to treatment. Treatment improved HbA1c from 6.9±0.9% (mean±SD) to 6.6±0.9%, with an effective response in 38.5%, an invalid response in 13.8%, and an invariable response in 47.7% of subjects. The three-month treatment improved insulin resistance, tripled the high-molecular-weight adiponectin serum level, significantly reduced low-density lipoprotein-cholesterol, increased high-density lipoprotein-cholesterol, and tended to reduce serum triglycerid. Safety analysis showed a mild weight gain of 1.5 kg and no hypoglycemia episodes. Our results indicated that glucose control can be improved together with insulin resistance, hypoadiponectinemia, and lipid profile. Weight gain was suppressed and hypoglycemia episodes minimized using pioglitazone combined with reduced doses of insulin secretion stimulators in subjects with type 2 diabetes.<br>

Journal

References(23)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top